Here's what Summer Street had to say about the Brean B.S. report........."Irrespective of what Brean Capital analyst Jonathan Aschoff says, his track record and any ulterior motives he may have (e.g. they are shorting the stock), its really the FDA that will make or break small cap dialysis stock Rockwell Medical." See for yourself just do a search for Summer Street Capital RMTI.